Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 299-309

  Harshyne, Larry A ^a   Hooper, Kirsten M ^a   Andrews, Edward G ^a   Nasca, Brian J ^a   Kenyon, Lawrence C ^a   Andrews, David W ^a   Hooper, D Craig ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antibody; Antisense; Diffusion chamber; Exosome; GL261; Glioblastoma

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD63 ANTIGEN; CD71 ANTIGEN; CD81 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INSULIN LIKE GROWTH FACTOR TYPE 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; POLY(METHYL METHACRYLATE); SOMATOMEDIN; UNCLASSIFIED DRUG; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTISENSE THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; DRUG UPTAKE; ELECTRON MICROSCOPY; EXOSOME; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; RECTUS ABDOMINIS MUSCLE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; DRUG SCREENING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EXOSOMES; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RECEPTOR, IGF TYPE 1; TRANSLATIONAL MEDICAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925507240     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1622-z     Document Type: Article

References (43)

1. Andrews DW, Resnicoff M, Flanders AE et al (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19:2189–2200
2. Baserga R, Reiss K, Alder H, Pietrzkowski Z, Surmacz E (1992) Inhibition of cell cycle progression by antisense oligodeoxynucleotides. Ann N Y Acad Sci 660:64–69
3. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D (1995) The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem 270:29176–29181
4. Resnicoff M, Abraham D, Yutanawiboonchai W et al (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463–2469
5. Bauer S, Kirschning CJ, Hacker H et al (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98:9237–9242
6. Iho S, Yamamoto T, Takahashi T, Yamamoto S (1999) Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol 163:3642–3652
7. Kobayashi N, Hong C, Klinman DM, Shirota H (2013) Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J Immunol 190:1882–1889
8. Krieg AM, Yi AK, Matson S et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549
9. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036
10. Stein CA, Subasinghe C, Shinozuka K, Cohen JS (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16:3209–3221
11. Théry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579
12. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (1987) Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 262:9412–9420
13. Théry C, Boussac M, Véron P et al (2001) Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166:7309–7318
14. Raposo G, Nijman HW, Stoorvogel W et al (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1172
15. Wolfers J, Lozier A, Raposo G et al (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7:297–303
16. Clayton A, Court J, Navabi H et al (2001) Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 247:163–174
17. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol 17:879–887
18. Graner MW, Alzate O, Dechkovskaia AM et al (2009) Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23:1541–1557
19. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G (2002) The biogenesis and functions of exosomes. Traffic 3:321–330
20. Théry C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. Chapter 3: Unit 3.22. doi: 10.1002/0471143030.cb0322s30
21. Faure J, Lachenal G, Court M et al (2006) Exosomes are released by cultured cortical neurones. Mol Cell Neurosci 31:642–648
22. Kramer-Albers EM, Bretz N, Tenzer S, Winterstein C (2007) Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: trophic support for axons? Proteomics Clin Appl 1:1446–1461
23. Potolicchio I, Carven GJ, Xu X et al (2005) Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J Immunol 175:2237–2243
24. Zitvogel L, Regnault A, Lozier A et al (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4:594–600
25. Février B, Raposo G (2004) Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 16:415–421
26. Al-Nedawi K, Meehan B, Micallef J et al (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624
27. Skog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476
28. Wieckowski E, Whiteside TL (2006) Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res 36:247–254
29. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
30. Andre F, Schartz NE, Movassagh M et al (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360:295–305
31. Chaput N, Schartz NE, André F et al (2004) Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172:2137–2146
32. Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27:352–357
33. Mignot G, Roux S, Thery C, Ségura E, Zitvogel L (2006) Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 10:376–388
34. Morelli AE (2006) The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant 6:254–261
35. Peche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC (2006) Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transpl 6:1541–1550
36. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW (2005) Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11:5292–5299
37. Abraham D, Rotman HL, Haberstroh HF et al (1995) Strongyloides stercoralis: protective immunity to third-stage larvae inBALB/cByJ mice. Exp Parasitol 80:297–307
38. Tavernier J, Tuypens T, Verhee A et al (1995) Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci USA 92:5194–5198
39. Lee GR, Fields PE, Griffin TJ, Flavell RA (2003) Regulation of the Th2 cytokine locus by a locus control region. Immunity 19:145–153
40. Rolink AG, Thalmann P, Kikuchi Y, Erdei A (1990) Characterization of the interleukin 5-reactive splenic B cell population. Eur J Immunol 20:1949–1956
41. McHeyzer-Williams MG (1989) Combinations of interleukins 2, 4 and 5 regulate the secretion of murine immunoglobulin isotypes. Eur J Immunol 19:2025–2030
42. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67:2912–2915
43. Murphy KA, Erickson JR, Johnson CS et al (2014) CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol 192:224–233